312 related articles for article (PubMed ID: 15489838)
1. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Dobordzhginidze LM
Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
[No Abstract] [Full Text] [Related]
2. [Fenofibrate].
Yamashita T; Nakamura H
Nihon Rinsho; 2001 Mar; 59 Suppl 3():618-24. PubMed ID: 11347142
[No Abstract] [Full Text] [Related]
3. Implications of 4S evidence on baseline lipid levels.
Durrington PN
Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
[No Abstract] [Full Text] [Related]
4. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Sebestjen M; Keber I; Zegura B; Simcic S; Bozic M; Fressart MM; Stegnar M
Thromb Haemost; 2004 Nov; 92(5):1129-35. PubMed ID: 15543343
[TBL] [Abstract][Full Text] [Related]
5. Black soybean extract improves lipid profiles in fenofibrate-treated type 2 diabetics with postprandial hyperlipidemia.
Kusunoki M; Sato D; Tsutsumi K; Tsutsui H; Nakamura T; Oshida Y
J Med Food; 2015 Jun; 18(6):615-8. PubMed ID: 25651043
[TBL] [Abstract][Full Text] [Related]
6. Fibrates and homocysteine.
Young IS; Woodside JV
Nutrition; 2001; 17(11-12):973-4. PubMed ID: 11744353
[No Abstract] [Full Text] [Related]
7. Implications of 4S evidence on baseline lipid levels.
Ravnskov U
Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244
[No Abstract] [Full Text] [Related]
8. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Ansquer JC; Foucher C; Rattier S; Taskinen MR; Steiner G;
Am J Kidney Dis; 2005 Mar; 45(3):485-93. PubMed ID: 15754270
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
Forcheron F; Cachefo A; Thevenon S; Pinteur C; Beylot M
Diabetes; 2002 Dec; 51(12):3486-91. PubMed ID: 12453904
[TBL] [Abstract][Full Text] [Related]
13. Effect of halofenate on serum lipids.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
[No Abstract] [Full Text] [Related]
14. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
Krysiak R; Gilowski W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
[TBL] [Abstract][Full Text] [Related]
15. A case for lipid-lowering?
Durrington P
Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
[No Abstract] [Full Text] [Related]
16. Lipid-lowering drugs and homocysteine.
de Lorgeril M; Salen P; Paillard F; Lacan P; Richard G
Lancet; 1999 Jan; 353(9148):209-10. PubMed ID: 9923885
[No Abstract] [Full Text] [Related]
17. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
Achimastos A; Liberopoulos E; Nikas S; Bairaktari E; Miltiadous G; Tsimihodimos V; Elisaf M
Curr Med Res Opin; 2002; 18(2):59-63. PubMed ID: 12017210
[TBL] [Abstract][Full Text] [Related]
18. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
[TBL] [Abstract][Full Text] [Related]
19. [KLAS [Kanazawa Lipid Assessment Survey]].
Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
[No Abstract] [Full Text] [Related]
20. [Helsinki Heart Study].
Sekiya M; Ishibashi S
Nihon Rinsho; 2001 Mar; 59 Suppl 3():404-9. PubMed ID: 11347103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
